Shineco (NASDAQ:SISI – Get Free Report) and Clene (NASDAQ:CLNN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
Institutional and Insider Ownership
4.1% of Shineco shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 0.0% of Shineco shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Shineco and Clene”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shineco | $9.60 million | 0.00 | -$22.45 million | ($204.00) | -0.00 |
| Clene | $200,000.00 | 254.60 | -$26.17 million | ($3.50) | -1.12 |
Shineco has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Shineco has a beta of -1.76, suggesting that its stock price is 276% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Shineco and Clene, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shineco | 0 | 0 | 0 | 0 | 0.00 |
| Clene | 1 | 0 | 6 | 0 | 2.71 |
Clene has a consensus price target of $34.00, indicating a potential upside of 767.35%. Given Clene’s stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Shineco.
Profitability
This table compares Shineco and Clene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shineco | -380.55% | -79.89% | -33.01% |
| Clene | -20,063.96% | N/A | -137.04% |
Summary
Clene beats Shineco on 9 of the 14 factors compared between the two stocks.
About Shineco
Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.
About Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Shineco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shineco and related companies with MarketBeat.com's FREE daily email newsletter.
